About this Journal Submit a Manuscript Table of Contents
Journal of Lipids
Volume 2011 (2011), Article ID 783976, 14 pages
http://dx.doi.org/10.1155/2011/783976
Review Article

Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation

Center for Functional Genomic and Biochips, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia

Received 4 January 2011; Revised 26 April 2011; Accepted 27 April 2011

Academic Editor: Shinichi Oikawa

Copyright © 2011 Klementina Fon Tacer and Damjana Rozman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. S. Rector, J. P. Thyfault, Y. Wei, and J. A. Ibdah, “Non-alcoholic fatty liver disease and the metabolic syndrome: an update,” World Journal of Gastroenterology, vol. 14, no. 2, pp. 185–192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Lazo and J. M. Clark, “The epidemiology of nonalcoholic fatty liver disease: a global perspective,” Seminars in Liver Disease, vol. 28, no. 4, pp. 339–350, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. I. Janssen, P. T. Katzmarzyk, W. F. Boyce et al., “Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns,” Obesity Reviews, vol. 6, no. 2, pp. 123–132, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. H. S. Park, J. H. Han, K. M. Choi, and S. M. Kim, “Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents,” American Journal of Clinical Nutrition, vol. 82, no. 5, pp. 1046–1051, 2005. View at Scopus
  5. N. J. Barshop, C. B. Sirlin, J. B. Schwimmer, and J. E. Lavine, “Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 1, pp. 13–24, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. G. Marchesini, M. Brizi, G. Blanchi et al., “Nonalcoholic fatty liver disease: a feature of the metabolic syndrome,” Diabetes, vol. 50, no. 8, pp. 1844–1850, 2001. View at Scopus
  7. B. A. Neuschwander-Tetri and S. H. Caldwell, “Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference,” Hepatology, vol. 37, no. 5, pp. 1202–1219, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. R. K. Schindhelm, R. J. Heine, and M. Diamant, “Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients,” Diabetes Care, vol. 30, no. 9, p. e94, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. P. Loria, A. Lonardo, S. Bellentani, C. P. Day, G. Marchesini, and N. Carulli, “Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 17, no. 9, pp. 684–698, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. K. Musunuru, “Atherogenic dyslipidemia: cardiovascular risk and dietary intervention,” Lipids, vol. 45, pp. 907–914, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. Kotronen and H. Yki-Järvinen, “Fatty liver: a novel component of the metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 1, pp. 27–38, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Hamaguchi, T. Kojima, N. Takeda et al., “Nonalcolholic fatty liver disease is a novel predictor cardiovascular disease,” World Journal of Gastroenterology, vol. 13, no. 10, pp. 1579–1584, 2007. View at Scopus
  13. G. Targher, L. Bertolini, R. Padovani et al., “Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes,” Journal of Hepatology, vol. 53, no. 4, pp. 713–718, 2010. View at Publisher · View at Google Scholar · View at PubMed
  14. M. Ekstedt, L. E. Franzén, U. L. Mathiesen et al., “Long-term follow-up of patients with NAFLD and elevated liver enzymes,” Hepatology, vol. 44, no. 4, pp. 865–873, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. L. McKimmie, K. R. Daniel, J. J. Carr et al., “Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study,” American Journal of Gastroenterology, vol. 103, no. 12, pp. 3029–3035, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. C. P. Day and O. F. W. James, “Steatohepatitis: a tale of two 'hits'?” Gastroenterology, vol. 114, no. 4, pp. 842–845, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. A. M. G. Cali, T. L. Zern, S. E. Taksali et al., “Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state,” Diabetes Care, vol. 30, no. 12, pp. 3093–3098, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. C. J. Packard and J. Shepherd, “Lipoprotein heterogeneity and apolipoprotein B metabolism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 12, pp. 3542–3556, 1997.
  19. D. Lucero, V. Zago, G. I. López et al., “Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?” Clinica Chimica Acta, vol. 412, no. 7-8, pp. 587–592, 2011. View at Publisher · View at Google Scholar · View at PubMed
  20. K. F. Petersen, S. Dufour, A. Hariri et al., “Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease,” New England Journal of Medicine, vol. 362, no. 12, pp. 1082–1089, 2010. View at Publisher · View at Google Scholar · View at PubMed
  21. B. Verggès, “New insight into the pathophysiology of lipid abnormalities in type 2 diabetes,” Diabetes and Metabolism, vol. 31, no. 5, pp. 429–439, 2005.
  22. J. Kozlitina, E. Boerwinkle, J. C. Cohen, and H. H. Hobbs, “Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance,” Hepatology, vol. 53, no. 2, pp. 467–474, 2011. View at Publisher · View at Google Scholar
  23. M. Nakamuta, T. Fujino, R. Yada et al., “Impact of cholesterol metabolism and the LXRα-SREBP-1c pathway on nonalcoholic fatty liver disease,” International Journal of Molecular Medicine, vol. 23, no. 5, pp. 603–608, 2009. View at Publisher · View at Google Scholar
  24. S. O. Olofsson, P. Stillemark-Billton, and L. Asp, “Intracellular assembly of VLDL: two major steps in separate cell compartments,” Trends in Cardiovascular Medicine, vol. 10, no. 8, pp. 338–345, 2000. View at Publisher · View at Google Scholar
  25. C. Namikawa, Z. Shu-Ping, J. R. Vyselaar et al., “Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 40, no. 5, pp. 781–786, 2004. View at Publisher · View at Google Scholar · View at PubMed
  26. R. Gambino, S. Bo, G. Musso et al., “Microsomal triglyceride transfer protein 493-T variant is associated with resistin levels and C-reactive protein,” Clinical Biochemistry, vol. 40, no. 16-17, pp. 1219–1224, 2007. View at Publisher · View at Google Scholar · View at PubMed
  27. M. Kjolby, O. M. Andersen, T. Breiderhoff et al., “Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export,” Cell Metabolism, vol. 12, no. 3, pp. 213–223, 2010. View at Publisher · View at Google Scholar · View at PubMed
  28. K. Musunuru, A. Strong, M. Frank-Kamenetsky et al., “From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus,” Nature, vol. 466, no. 7307, pp. 714–719, 2010. View at Publisher · View at Google Scholar · View at PubMed
  29. P. Linsel-Nitschke, J. Heeren, Z. Aherrahrou et al., “Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease,” Atherosclerosis, vol. 208, no. 1, pp. 183–189, 2010. View at Publisher · View at Google Scholar · View at PubMed
  30. J. D. Horton, J. C. Cohen, and H. H. Hobbs, “Molecular biology of PCSK9: its role in LDL metabolism,” Trends in Biochemical Sciences, vol. 32, no. 2, pp. 71–77, 2007. View at Publisher · View at Google Scholar · View at PubMed
  31. A. Zaid, A. Roubtsova, R. Essalmani et al., “Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration,” Hepatology, vol. 48, no. 2, pp. 646–654, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. H. N. Ginsberg, Y. L. Zhang, and A. Hernandez-Ono, “Regulation of plasma triglycerides in insulin resistance and diabetes,” Archives of Medical Research, vol. 36, no. 3, pp. 232–240, 2005. View at Publisher · View at Google Scholar · View at PubMed
  33. P. J. Voshol, G. Haemmerle, D. M. Ouwens et al., “Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice,” Endocrinology, vol. 144, no. 8, pp. 3456–3462, 2003. View at Publisher · View at Google Scholar
  34. I. J. Goldberg, R. H. Eckel, and N. A. Abumrad, “Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways,” Journal of Lipid Research, vol. 50, pp. S86–S90, 2009. View at Publisher · View at Google Scholar · View at PubMed
  35. C. Z. Larter, M. M. Yeh, D. M. Van Rooyen et al., “Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice,” Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1658–1668, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. L. Zhu, S. S. Baker, W. Liu et al., “Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis,” Metabolism, vol. 60, pp. 1001–1011, 2010. View at Publisher · View at Google Scholar · View at PubMed
  37. L. P. Bechmann, R. K. Gieseler, J. P. Sowa et al., “Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis,” Liver International, vol. 30, no. 6, pp. 850–859, 2010. View at Publisher · View at Google Scholar · View at PubMed
  38. V. Luangrath, M. R. Brodeur, D. Rhainds, and L. Brissette, “Mouse CD36 has opposite effects on LDL and oxidized LDL metabolism in vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 7, pp. 1290–1295, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. G. Endemann, L. W. Stanton, K. S. Madden, C. M. Bryant, R. T. White, and A. A. Protter, “CD36 is a receptor for oxidized low density lipoprotein,” Journal of Biological Chemistry, vol. 268, no. 16, pp. 11811–11816, 1993.
  40. M. Febbraio, E. Guy, C. Coburn, et al., “The impact of overexpression and deficiency of fatty acid translocase (FAT)/CD36,” in Molecular and Cellular Biochemistry, pp. 193–197, Springer, Amsterdam, The Netherlands, 2002.
  41. C. Dorn, M.-O. Riener, G. Kirovski et al., “Expression of fatty acid synthase in nonalcoholic fatty liver disease,” International Journal of Clinical and Experimental Pathology, vol. 3, no. 5, pp. 505–514, 2010.
  42. D. B. Savage, S. C. Cheol, V. T. Samuel et al., “Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 817–824, 2006. View at Publisher · View at Google Scholar · View at PubMed
  43. G. Jiang, Z. Li, F. Liu et al., “Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1,” Journal of Clinical Investigation, vol. 115, no. 4, pp. 1030–1038, 2005. View at Publisher · View at Google Scholar
  44. P. Cohen, M. Miyazaki, N. D. Socci et al., “Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss,” Science, vol. 297, no. 5579, pp. 240–243, 2002. View at Publisher · View at Google Scholar · View at PubMed
  45. J. M. Ntambi, M. Miyazaki, J. P. Stoehr et al., “Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11482–11486, 2002. View at Publisher · View at Google Scholar · View at PubMed
  46. T. Matsuzaka, H. Shimano, N. Yahagi et al., “Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance,” Nature Medicine, vol. 13, no. 10, pp. 1193–1202, 2007. View at Publisher · View at Google Scholar · View at PubMed
  47. J. Araya, R. Rodrigo, P. Pettinelli, A. V. Araya, J. Poniachik, and L. A. Videla, “Decreased liver fatty Acid δ-6 and δ-5 desaturase activity in obese patients,” Obesity, vol. 18, no. 7, pp. 1460–1463, 2010. View at Publisher · View at Google Scholar · View at PubMed
  48. J. G. Gormaz, R. Rodrigo, L. A. Videla, and M. Beems, “Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease,” Progress in Lipid Research, vol. 49, pp. 407–419, 2010. View at Publisher · View at Google Scholar · View at PubMed
  49. I. Shimomura, Y. Bashmakov, S. Ikemoto, J. D. Horton, M. S. Brown, and J. L. Goldstein, “Insulin selectively increases SREBP-1C mRNA in the livers of rats with streptozotocin-induced diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 24, pp. 13656–13661, 1999. View at Publisher · View at Google Scholar
  50. M. Foretz, C. Guichard, P. Ferré, and F. Foufelle, “Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 22, pp. 12737–12742, 1999.
  51. R. Dentin, F. Benhamed, I. Hainault et al., “Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice,” Diabetes, vol. 55, no. 8, pp. 2159–2170, 2006. View at Publisher · View at Google Scholar · View at PubMed
  52. J. Bricambert, J. Miranda, F. Benhamed, J. Girard, C. Postic, and R. Dentin, “Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice,” Journal of Clinical Investigation, vol. 120, no. 12, pp. 4316–4331, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. J. D. Horton, N. A. Shah, J. A. Warrington et al., “Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12027–12032, 2003. View at Publisher · View at Google Scholar · View at PubMed
  54. J. D. McGarry, G. P. Mannaerts, and D. W. Foster, “A possible role for malonyl CoA in the regulation of hepatic fatty acid oxidation and ketogenesis,” Journal of Clinical Investigation, vol. 60, no. 1, pp. 265–270, 1977.
  55. S. C. Cheol, D. B. Savage, A. Kulkarni et al., “Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance,” Journal of Biological Chemistry, vol. 282, no. 31, pp. 22678–22688, 2007. View at Publisher · View at Google Scholar · View at PubMed
  56. X. X. Yu, S. F. Murray, S. K. Pandey et al., “Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice,” Hepatology, vol. 42, no. 2, pp. 362–371, 2005. View at Publisher · View at Google Scholar · View at PubMed
  57. K. Yamaguchi, L. Yang, S. McCall et al., “Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis,” Hepatology, vol. 45, no. 6, pp. 1366–1374, 2007. View at Publisher · View at Google Scholar · View at PubMed
  58. S. Turpin, A. Hoy, R. Brown, et al., “Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice,” in Diabetologia, pp. 146–156, Springer, Berlin, Germany, 2011.
  59. N. Stefan, H. Staiger, and H.-U. Haring, “Dissociation between fatty liver and insulin resistance: the role of adipose triacylglycerol lipase,” in Diabetologia, pp. 7–9, Springer, Berlin, Germany, 2011.
  60. J. M. Brown, J. L. Betters, C. Lord et al., “CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance,” Journal of Lipid Research, vol. 51, no. 11, pp. 3306–3315, 2010. View at Publisher · View at Google Scholar · View at PubMed
  61. M. S. Brown and J. L. Goldstein, “The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor,” Cell, vol. 89, no. 3, pp. 331–340, 1997. View at Publisher · View at Google Scholar
  62. D. J. Peet, B. A. Janowski, and D. J. Mangelsdorf, “The LXRs: a new class of oxysterol receptors,” Current Opinion in Genetics and Development, vol. 8, no. 5, pp. 571–575, 1998. View at Publisher · View at Google Scholar
  63. J. J. Repa and D. J. Mangelsdorf, “The liver X receptor gene team: potential new players in atherosclerosis,” Nature Medicine, vol. 8, no. 11, pp. 1243–1248, 2002. View at Publisher · View at Google Scholar · View at PubMed
  64. P. J. Willy, K. Umesono, E. S. Ong, R. M. Evans, R. A. Heyman, and D. J. Mangelsdorf, “LXR, a nuclear receptor that defines a distinct retinoid response pathway,” Genes and Development, vol. 9, no. 9, pp. 1033–1045, 1995.
  65. N. Zelcer, C. Hong, R. Boyadjian, and P. Tontonoz, “LXR regulates cholesterol uptake through idol-dependent ubiquitination of the LDL receptor,” Science, vol. 325, no. 5936, pp. 100–104, 2009. View at Publisher · View at Google Scholar · View at PubMed
  66. H. M. Alger, J. Mark Brown, J. K. Sawyer et al., “Inhibition of acyl-coenzyme A: cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization,” Journal of Biological Chemistry, vol. 285, no. 19, pp. 14267–14274, 2010. View at Publisher · View at Google Scholar · View at PubMed
  67. S. W. Altmann, H. R. Davis Jr., L.-J. Zhu et al., “Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption,” Science, vol. 303, no. 5661, pp. 1201–1204, 2004. View at Publisher · View at Google Scholar · View at PubMed
  68. S. Yamagishi, K. Nakamura, T. Matsui, T. Sato, and M. Takeuchi, “Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver,” Medical Hypotheses, vol. 66, no. 4, pp. 844–846, 2006. View at Publisher · View at Google Scholar · View at PubMed
  69. T. N. Tulenko and A. E. Sumner, “The physiology of lipoproteins,” Journal of Nuclear Cardiology, vol. 9, no. 6, pp. 638–649, 2002. View at Publisher · View at Google Scholar · View at PubMed
  70. M. S. Brown and J. L. Goldstein, “A receptor-mediated pathway for cholesterol homeostasis,” Science, vol. 232, no. 4746, pp. 34–47, 1986.
  71. M. Adiels, S. O. Olofsson, M. R. Taskinen, and J. Borén, “Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 7, pp. 1225–1236, 2008. View at Publisher · View at Google Scholar · View at PubMed
  72. M. Haidari, N. Leung, F. Mahbub et al., “Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance,” Journal of Biological Chemistry, vol. 277, no. 35, pp. 31646–31655, 2002. View at Publisher · View at Google Scholar · View at PubMed
  73. M. Zoltowska, E. Ziv, E. Delvin et al., “Circulating lipoproteins and hepatic sterol metabolism in Psammomys obesus prone to obesity, hyperglycemia and hyperinsulinemia,” Atherosclerosis, vol. 157, no. 1, pp. 85–96, 2001. View at Publisher · View at Google Scholar
  74. D. Singh, P. Sakhuja, V. Malhotra, R. Gondal, and S. Sarin, “Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis,” in Digestive Diseases and Sciences, pp. 1967–1976, Springer, Amsterdam, The Netherlands, 2008.
  75. I. Sugino, K. Kuboki, T. Matsumoto, E. Murakami, C. Nishimura, and G. Yoshino, “Influence of fatty liver on plasma small, dense LDL-cholesterol in subjects with and without metabolic syndrome,” Journal of Atherosclerosis and Thrombosis, vol. 18, no. 1, pp. 1–7, 2011.
  76. F. G. S. Toledo, A. D. Sniderman, and D. E. Kelley, “Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes,” Diabetes Care, vol. 29, no. 8, pp. 1845–1850, 2006. View at Publisher · View at Google Scholar · View at PubMed
  77. Y. Toyota, T. Yamamura, Y. Miyake, and A. Yamamoto, “Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia,” Atherosclerosis, vol. 147, no. 1, pp. 77–86, 1999. View at Publisher · View at Google Scholar
  78. K. Fujita, Y. Nozaki, K. Wada et al., “Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis,” Hepatology, vol. 50, no. 3, pp. 772–780, 2009. View at Publisher · View at Google Scholar · View at PubMed
  79. X. Q. Deng, L. L. Chen, and N. X. Li, “The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats,” Liver International, vol. 27, no. 5, pp. 708–715, 2007. View at Publisher · View at Google Scholar · View at PubMed
  80. K. Kawaguchi, I. Sakaida, M. Tsuchiya, K. Omori, T. Takami, and K. Okita, “Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet,” Biochemical and Biophysical Research Communications, vol. 315, no. 1, pp. 187–195, 2004. View at Publisher · View at Google Scholar · View at PubMed
  81. K. Fujita, Y. Nozaki, K. Wada et al., “Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease,” Gut, vol. 57, no. 11, pp. 1583–1591, 2008. View at Publisher · View at Google Scholar · View at PubMed
  82. J. Björkegren, A. Beigneux, M. O. Bergo, J. J. Maher, and S. G. Young, “Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury,” Journal of Biological Chemistry, vol. 277, no. 7, pp. 5476–5483, 2002. View at Publisher · View at Google Scholar · View at PubMed
  83. M. Raabe, M. M. Véniant, M. A. Sullivan et al., “Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice,” Journal of Clinical Investigation, vol. 103, no. 9, pp. 1287–1298, 1999.
  84. K. Minehira, S. G. Young, C. J. Villanueva et al., “Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice,” Journal of Lipid Research, vol. 49, no. 9, pp. 2038–2044, 2008. View at Publisher · View at Google Scholar · View at PubMed
  85. X. Chang, H. Yan, J. Fei et al., “Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats,” Journal of Lipid Research, vol. 51, no. 9, pp. 2504–2515, 2010. View at Publisher · View at Google Scholar · View at PubMed
  86. D. Owens, “The extended postprandial phase in diabetes,” Biochemical Society Transactions, vol. 31, no. 5, pp. 1085–1089, 2003.
  87. Q. Kang and A. Chen, “Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells,” British Journal of Pharmacology, vol. 157, no. 8, pp. 1354–1367, 2009. View at Publisher · View at Google Scholar · View at PubMed
  88. J. L. Goldstein and M. S. Brown, “The LDL receptor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 431–438, 2009. View at Publisher · View at Google Scholar · View at PubMed
  89. M. Abifadel, M. Varret, J. P. Rabès et al., “Mutations in PCSK9 cause autosomal dominant hypercholesterolemia,” Nature Genetics, vol. 34, no. 2, pp. 154–156, 2003. View at Publisher · View at Google Scholar · View at PubMed
  90. K. L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks, “Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1343–1351, 2005. View at Publisher · View at Google Scholar
  91. Y. D. I. Chen, A. Golay, A. L. M. Swislocki, and G. M. Reaven, “Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 64, no. 1, pp. 17–21, 1987.
  92. J. Zhou, M. Febbraio, T. Wada et al., “Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis,” Gastroenterology, vol. 134, no. 2, pp. 556–567, 2008. View at Publisher · View at Google Scholar · View at PubMed
  93. J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004. View at Publisher · View at Google Scholar
  94. A. J. Sanyal, C. Campbell-Sargent, F. Mirshahi et al., “Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities,” Gastroenterology, vol. 120, no. 5, pp. 1183–1192, 2001.
  95. J. Araya, R. Rodrigo, L. A. Videla et al., “Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease,” Clinical Science, vol. 106, no. 6, pp. 635–643, 2004. View at Publisher · View at Google Scholar · View at PubMed
  96. I. Shimomura, H. Shimano, B. S. Korn, Y. Bashmakov, and J. D. Horton, “Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver,” Journal of Biological Chemistry, vol. 273, no. 52, pp. 35299–35306, 1998. View at Publisher · View at Google Scholar
  97. J. Acimovic, A. Lövgren-Sandblom, K. Monostory et al., “Combined gas chromatographic/mass spectrometric analysis of cholesterol precursors and plant sterols in cultured cells,” Journal of Chromatography B, vol. 877, no. 22, pp. 2081–2086, 2009. View at Publisher · View at Google Scholar · View at PubMed
  98. M. H. Oosterveer, A. Grefhorst, T. H. van Dijk et al., “Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice,” Journal of Biological Chemistry, vol. 284, no. 49, pp. 34036–34044, 2009. View at Publisher · View at Google Scholar · View at PubMed
  99. F. A. M. Nascimento, S. Barbosa-da-Silva, C. Fernandes-Santos, C. A. Mandarim-de-Lacerda, and M. B. Aguila, “Adipose tissue, liver and pancreas structural alterations in C57BL/6 mice fed high-fat-high-sucrose diet supplemented with fish oil (n-3 fatty acid rich oil),” Experimental and Toxicologic Pathology, vol. 62, no. 1, pp. 17–25, 2010. View at Publisher · View at Google Scholar · View at PubMed
  100. H. Ando, T. Takamura, N. Matsuzawa-Nagata et al., “The hepatic circadian clock is preserved in a lipid-induced mouse model of non-alcoholic steatohepatitis,” Biochemical and Biophysical Research Communications, vol. 380, no. 3, pp. 684–688, 2009. View at Publisher · View at Google Scholar · View at PubMed
  101. T. P. Johnston, J. C. Baker, D. Hall, S. Jamal, W. K. Palmer, and E. E. Emeson, “Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin,” Atherosclerosis, vol. 149, no. 2, pp. 303–313, 2000. View at Publisher · View at Google Scholar
  102. L. Bünger, J. Forsting, K. L. McDonald et al., “Long-term divergent selection on fatness in mice indicates a regulation system independent of leptin production and reception,” The FASEB Journal, vol. 17, no. 1, pp. 85–87, 2003.
  103. S. Horvat, L. Bünger, V. M. Falconer et al., “Mapping of obesity QTLs in a cross between mouse lines divergently selected on fat content,” Mammalian Genome, vol. 11, no. 1, pp. 2–7, 2000. View at Publisher · View at Google Scholar
  104. I. M. Stylianou, M. Clinton, P. D. Keightley et al., “Microarray gene expression analysis of the Fob3b obesity QTL identifies positional candidate gene Sqle and perturbed cholesterol and glycolysis pathways,” Physiological Genomics, vol. 20, pp. 224–232, 2005. View at Publisher · View at Google Scholar · View at PubMed
  105. I. M. Stylianou, J. K. Christians, P. D. Keightley et al., “Genetic complexity of an obesity QTL (Fob3) revealed by detailed genetic mapping,” Mammalian Genome, vol. 15, no. 6, pp. 472–481, 2004. View at Publisher · View at Google Scholar · View at PubMed
  106. N. M. Morton, V. Densmore, M. Wamil et al., “A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action,” Diabetes, vol. 54, no. 12, pp. 3371–3378, 2005. View at Publisher · View at Google Scholar
  107. M. Simončič, S. Horvat, P. L. Stevenson et al., “Divergent physical activity and novel alternative responses to high fat feeding in polygenic fat and lean mice,” Behavior Genetics, vol. 38, no. 3, pp. 292–300, 2008. View at Publisher · View at Google Scholar · View at PubMed
  108. S. Horvat, J. McWhir, and D. Rozman, “Defects in cholesterol synthesis genes in mouse and in humans: lessons for drug development and safer treatments,” Drug Metabolism Reviews, vol. 43, no. 1, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at PubMed
  109. F. Foufelle and P. Ferré, “New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c,” Biochemical Journal, vol. 366, no. 2, pp. 377–391, 2002. View at Publisher · View at Google Scholar · View at PubMed
  110. H. Shimano, J. D. Horton, I. Shimomura, R. E. Hammer, M. S. Brown, and J. L. Goldstein, “Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells,” Journal of Clinical Investigation, vol. 99, no. 5, pp. 846–854, 1997.
  111. N. Yahagi, H. Shimano, A. H. Hasty et al., “Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep/Lep mice,” Journal of Biological Chemistry, vol. 277, no. 22, pp. 19353–19357, 2002. View at Publisher · View at Google Scholar · View at PubMed
  112. L. Abu-Elheiga, W. Oh, P. Kordari, and S. J. Wakil, “Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10207–10212, 2003. View at Publisher · View at Google Scholar · View at PubMed
  113. K. Uyeda, H. Yamashita, and T. Kawaguchi, “Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage,” Biochemical Pharmacology, vol. 63, no. 12, pp. 2075–2080, 2002. View at Publisher · View at Google Scholar
  114. H. Yamashita, M. Takenoshita, M. Sakurai et al., “A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 16, pp. 9116–9121, 2001. View at Publisher · View at Google Scholar · View at PubMed
  115. S. Ishii, K. Ilzuka, B. C. Miller, and K. Uyeda, “Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 44, pp. 15597–15602, 2004. View at Publisher · View at Google Scholar · View at PubMed
  116. C. A. Nagle, E. L. Klett, and R. A. Coleman, “Hepatic triacylglycerol accumulation and insulin resistance,” Journal of Lipid Research, vol. 50, pp. S74–S79, 2009. View at Publisher · View at Google Scholar · View at PubMed
  117. H. N. Ginsberg, Y.-L. Zhang, and A. Hernandez-Ono, “Regulation of plasma triglycerides in insulin resistance and diabetes,” Archives of Medical Research, vol. 36, no. 3, pp. 232–240, 2005. View at Publisher · View at Google Scholar · View at PubMed
  118. J. Pihlajamäki, H. Gylling, T. A. Miettinen, and M. Laakso, “Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men,” Journal of Lipid Research, vol. 45, no. 3, pp. 507–512, 2004. View at Publisher · View at Google Scholar · View at PubMed
  119. H. Gylling, M. Hallikainen, J. Pihlajamäki et al., “Insulin sensitivity regulates cholesterol metabolism to a greater extent than obesity: lessons from the METSIM study,” Journal of Lipid Research, vol. 51, no. 8, pp. 2422–2427, 2010. View at Publisher · View at Google Scholar · View at PubMed
  120. P. Simonen, A. Kotronen, M. Hallikainen et al., “Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity,” Journal of Hepatology, vol. 54, no. 1, pp. 153–159, 2011. View at Publisher · View at Google Scholar · View at PubMed
  121. M. Kainuma, M. Fujimoto, N. Sekiya et al., “Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis,” Journal of Gastroenterology, vol. 41, no. 10, pp. 971–980, 2006. View at Publisher · View at Google Scholar · View at PubMed
  122. N. Matsuzawa, T. Takamura, S. Kurita et al., “Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet,” Hepatology, vol. 46, no. 5, pp. 1392–1403, 2007. View at Publisher · View at Google Scholar · View at PubMed
  123. M. Marí, F. Caballero, A. Colell et al., “Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis,” Cell Metabolism, vol. 4, no. 3, pp. 185–198, 2006. View at Publisher · View at Google Scholar · View at PubMed
  124. K. Wouters, P. J. van Gorp, V. Bieghs et al., “Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis,” Hepatology, vol. 48, no. 2, pp. 474–486, 2008. View at Publisher · View at Google Scholar · View at PubMed
  125. G. S. Hotamisligil, “Inflammatory pathways and insulin action,” International Journal of Obesity, vol. 27, supplement 3, pp. S53–S55, 2003. View at Publisher · View at Google Scholar · View at PubMed
  126. K. T. Uysal, S. M. Wiesbrock, M. W. Marino, and G. S. Hotamisligil, “Protection from obesity-induced insulin resistance in mice lacking TNF-α function,” Nature, vol. 389, no. 6651, pp. 610–614, 1997. View at Publisher · View at Google Scholar · View at PubMed
  127. Y. Iimuro, R. M. Gallucci, M. Luster, H. Kono, and R. G. Thurman, “Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat,” Hepatology, vol. 26, no. 6, pp. 1530–1537, 1997.
  128. M. Yin, M. D. Wheeler, H. Kono et al., “Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice,” Gastroenterology, vol. 117, no. 4, pp. 942–952, 1999. View at Publisher · View at Google Scholar
  129. K. F. Tacer, D. Kuzman, M. Seliškar, D. Pompon, and D. Rozman, “TNF-α interferes with lipid homeostasis and activates acute and proatherogenic processes,” Physiological Genomics, vol. 31, no. 2, pp. 216–227, 2007. View at Publisher · View at Google Scholar · View at PubMed
  130. K. Fon Tacer, D. Pompon, and D. Rozman, “Adaptation of cholesterol synthesis to fasting and TNF-α: profiling cholesterol intermediates in the liver, brain, and testis,” Journal of Steroid Biochemistry and Molecular Biology, vol. 121, no. 3–5, pp. 619–625, 2010. View at Publisher · View at Google Scholar · View at PubMed
  131. A. Moreau, C. Téruel, M. Beylot et al., “A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte,” Hepatology, vol. 49, no. 6, pp. 2068–2079, 2009. View at Publisher · View at Google Scholar · View at PubMed
  132. T. Režen, V. Tamasi, A. Lövgren-Sandblom, I. Björkhem, U. A. Meyer, and D. Rozman, “Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers,” BMC Genomics, vol. 10, Article ID 1471, p. 384, 2009. View at Publisher · View at Google Scholar · View at PubMed
  133. D. J. Peet, S. D. Turley, W. Ma et al., “Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα,” Cell, vol. 93, no. 5, pp. 693–704, 1998. View at Publisher · View at Google Scholar
  134. J. J. Repa, G. Liang, J. Ou et al., “Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ,” Genes and Development, vol. 14, no. 22, pp. 2819–2830, 2000. View at Publisher · View at Google Scholar
  135. J. R. Schultz, H. Tu, A. Luk et al., “Role of LXRs in control of lipogenesis,” Genes and Development, vol. 14, no. 22, pp. 2831–2838, 2000. View at Publisher · View at Google Scholar
  136. G. Chen, G. Liang, J. Ou, J. L. Goldstein, and M. S. Brown, “Central role for liver X receptor in insulin-mediated activation of SREBP-1c transcription and stimulation of fatty acid synthesis in liver,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 31, pp. 11245–11250, 2004. View at Publisher · View at Google Scholar · View at PubMed
  137. S. B. Joseph, B. A. Laffitte, P. H. Patel et al., “Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors,” Journal of Biological Chemistry, vol. 277, no. 13, pp. 11019–11025, 2002. View at Publisher · View at Google Scholar · View at PubMed
  138. S. Talukdar and F. B. Hillgartner, “The mechanism mediating the activation of acetyl-coenzyme A carboxylase-α gene transcription by the liver X receptor agonist T0-901317,” Journal of Lipid Research, vol. 47, no. 11, pp. 2451–2461, 2006. View at Publisher · View at Google Scholar · View at PubMed
  139. J.-Y. Cha and J. J. Repa, “The liver X Receptor (LXR) and hepatic lipogenesis: the carbohydrate-response element-binding protein is a target gene of LXR,” Journal of Biological Chemistry, vol. 282, no. 1, pp. 743–751, 2007. View at Publisher · View at Google Scholar · View at PubMed
  140. L. L. Rudel, R. G. Lee, and P. Parini, “ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 6, pp. 1112–1118, 2005. View at Publisher · View at Google Scholar · View at PubMed
  141. T. D. Filippatos and M. S. Elisaf, “Combination drug treatment in patients with non-alcoholic fatty liver disease,” World Journal of Hepatology, vol. 2, pp. 139–142, 2010.
  142. T. A. Bowman, S. K. Ramakrishnan, M. Kaw et al., “Caloric restriction reverses hepatic insulin resistance and steatosis in rats with low aerobic capacity,” Endocrinology, vol. 151, no. 11, pp. 5157–5164, 2010. View at Publisher · View at Google Scholar · View at PubMed
  143. M. Ekstedt, L. E. Franzén, U. L. Mathiesen, M. Holmqvist, G. Bodemar, and S. Kechagias, “Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study>,” Journal of Hepatology, vol. 47, no. 1, pp. 135–141, 2007. View at Publisher · View at Google Scholar · View at PubMed
  144. T. Foster, M. J. Budoff, S. Saab, N. Ahmadi, C. Gordon, and A. D. Guerci, “Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the st francis heart study randomized clinical trial,” American Journal of Gastroenterology, vol. 106, no. 1, pp. 71–77, 2011. View at Publisher · View at Google Scholar · View at PubMed
  145. D. Rozman and K. Monostory, “Perspectives of the non-statin hypolipidemic agents,” Pharmacology and Therapeutics, vol. 127, no. 1, pp. 19–40, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  146. J.-J. Tang, J.-G. Li, W. Qi et al., “Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques,” Cell Metabolism, vol. 13, no. 1, pp. 44–56, 2011. View at Publisher · View at Google Scholar · View at PubMed
  147. M. Deushi, M. Nomura, A. Kawakami et al., “Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome,” FEBS Letters, vol. 581, no. 29, pp. 5664–5670, 2007. View at Publisher · View at Google Scholar · View at PubMed
  148. M. Enjoji, K. Machida, M. Kohjima et al., “NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease,” Lipids in Health and Disease, vol. 9, p. 29, 2010.
  149. M. A. Valasek, S. L. Clarke, and J. J. Repa, “Fenofibrate reduces intestinal cholesterol absorption via PPARα-dependent modulation of NPC1L1 expression in mouse,” Journal of Lipid Research, vol. 48, no. 12, pp. 2725–2735, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  150. A. C. Goldberg, A. Sapre, J. Liu, R. Capece, and Y. B. Mitchel, “Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial,” Mayo Clinic Proceedings, vol. 79, no. 5, pp. 620–629, 2004. View at Scopus
  151. T. Ábel, J. Fehér, E. Dinya, M. G. Eldin, and A. Kovács, “Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease,” Medical Science Monitor, vol. 15, no. 12, pp. MS6–MS11, 2009. View at Scopus